Table 1.
Characteristics of 193 patients with COVID-19.
| Total (n = 193) | BMI, Kg/m 2 | P -value | ||||
|---|---|---|---|---|---|---|
| Normal (n = 112, 58.03%) | Underweight (n = 11, 5.70%) |
Overweight (n = 54, 27.98%) |
Obesity (n = 16, 8.29%) | |||
| Age, year, Median (IQR) | 39 (32–56.5) | 37.5 (31–54.75) | 36 (31-61) | 40.5 (33.75–57.25) | 44 (38-55) | 0.236 |
| Males, N (%) | 71/193 (36.79) | 32/112 (28.57) | 1/11 (9.09) | 27/54 (50) | 11/16 (68.75) | < 0.001 |
| Personal coexisting chronic disease, N (%) | ||||||
| Hypertension | 54/193 (27.98) | 22/112 (19.64) | 2/11 (18.18) | 20/54 (37.04) | 10/16 (62.50) | < 0.001 |
| Malignant tumor | 18/193 (9.33) | 11/112 (9.82) | 0/11 (0) | 5/54 (9.26) | 2/16 (12.5) | 0.824 |
| Diabetes | 17/193 (8.81) | 9/112 (8.04) | 0/11 (0) | 8/54 (14.81) | 0/16 (0) | 0.236 |
| Cardiovascular disease | 57/193 (29.53) | 24/112 (21.43) | 2/11 (18.18) | 21/54 (38.87) | 10/16 (62.50) | 0.002 |
| Initial symptoms, N (%) | ||||||
| Fever | 160/193 (82.90) | 89/112 (79.46) | 9/11 (81.82) | 48/54 (88.89) | 14/16 (87.50) | 0.491 |
| Cough | 121/193 (62.69) | 70/112 (62.50) | 7/11 (63.64) | 35/54 (64.81) | 9/16 (56.25) | 0.145 |
| Fatigue | 94/193 (48.70) | 48/112 (42.86) | 4/11 (36.36) | 32/54 (59.26) | 10/16 (62.50) | 0.122 |
| Headache | 24/193 (12.44) | 13/112 (11.61) | 4/11 (36.36) | 4/54 (7.41) | 3/16 (18.75) | 0.029 |
| Diarrhea | 32/193 (16.58) | 20/112 (17.86) | 2/11 (18.18) | 8/54 (14.81) | 2/16 (12.5) | 0.932 |
| Sore throat | 29/193 (15.03) | 17/112 (15.18) | 4/11 (36.36) | 6/54 (11.11) | 2/16 (12.5) | 0.224 |
| Shortness of breath | 63/193 (32.64) | 38/112 (33.93) | 3/11 (27.27) | 15/54 (27.78) | 7/16 (43.75) | 0.632 |
| Disease progression, days, Median (IQR) | ||||||
| From onset to hospitalization | 7 (5-12) | 8 (6-14) | 5 (3-15) | 7 (4.75–10.25) | 7 (4.25–8.75) | 0.291 |
| From onset to dyspnea | 5.5 (3–7.25) | 6 (4.5–8) | 6 (1) | 5 (2-6) | 4 (0–8) | 0.120 |
| From onset to ARDS | 8 (7-11) | 11 (7-29) | - | 9 (5.5–10) | 7 (7-7) | 0.500 |
| From onset to discharge | 25 (20-34) | 26 (21–37.5) | 31 (21-43) | 23 (17.75–28) | 22 (19.25–30) | 0.072 |
| Auxiliary examination results | ||||||
| Lymphocytes below normal (< 1.1 G/L), N (%) | 70/193 (36.27) | 45/112 (40.18) | 4/11 (36.36) | 12/54 (22.22) | 9/16 (56.25) | 0.038 |
| Albumin below normal(< 35 g/L), N (%) | 27/193 (13.99) | 16/112 (14.29) | 2/11 (18.18) | 6/54 (11.11) | 3/16 (18.75) | 0.726 |
| Prealbumin below normal (<0.17 g/L), N (%) | 72/180 (40) | 39/102 (38.24) | 6/10 (60) | 19/52 (36.54) | 8/16 (50) | 0.421 |
| CRP above normal (≥8 mg/L), N (%) | 98/192 (51.04) | 52/111 (46.85) | 2/11 (18.18) | 34/54 (62.96) | 10/16 (62.50) | 0.023 |
| lung CT scans | ||||||
| Bilateral multiple mottling and groundglass opacity, N (%) | 93/193 (48.19) | 49/112 (43.75) | 4/11 (36.36) | 26 (48.15) | 14/16 (87.50) | 0.007 |
| Severity of COVID-19 | ||||||
| Acute lung injury, N (%) | 96/193 (49.74) | 48/112 (42.86) | 8/11 (72.73) | 26 (48.15) | 14/16 (87.50) | 0.003 |
| ARDS, N (%) | 18/193 (9.33) | 9/112 (8.18) | 1/11 (9.09) | 5 (9.26) | 3/16 (18.75) | 0.478 |
| Secondary infection, N (%) | 30/193 (15.54) | 13/112 (11.61) | 4/11 (36.36) | 10 (18.52) | 3/16 (18.75) | 0.116 |
| Treatment | ||||||
| Combination of antibiotics were administered after admission, N (%) | 101/193 (52.33) | 54/112 (48.21) | 8/11 (72.73) | 28 (51.85) | 11/16 (68.75) | 0.234 |
| Human immunoglobulin+systematic corticosteroids, N (%) | 49/193 (25.39) | 21/112 (18.75) | 2/11 (18.18) | 19 (35.19) | 7/16 (43.75) | 0.036 |
| oxygen therapy, N (%) | 143/193 (74.09) | 78/112 (69.64) | 9/11 (81.82) | 42 (77.78) | 14/16 (87.5) | 0.343 |
BMI, body mass index; ARDS, acute respiratory distress syndrome.